Forbion Eyes Late-Stage Opportunities With New Fund
Venture Capital Firm Raises Initial €470m
Executive Summary
Looking to take advantage of the cool reception private biotechs are receiving from the public markets, a leading European VC is targeting investments of up to €70m per deal in firms with undervalued late-stage assets.
You may also be interested in...
ARCH Cites Stability Of Long-Term Investors In Raising $3bn Fund
ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.
Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
Ups And Downs In Protein Degraders: Big Deals For BMS, Merck KGaA, Safety Worries For Kymera
Kymera has seen its share price fall more than 30% this week as investors struggle to gauge how much future market potential targeted protein degraders will have.